Aquestive Therapeutics (NASDAQ:AQST) Given Buy Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Aquestive Therapeutics (NASDAQ:AQST) in a research report released on Wednesday, Benzinga reports. HC Wainwright currently has a $10.00 price objective on the stock.

A number of other equities research analysts have also recently issued reports on the company. JMP Securities restated a “market outperform” rating and issued a $9.00 price objective on shares of Aquestive Therapeutics in a research note on Tuesday, October 8th. Leerink Partners raised their price objective on shares of Aquestive Therapeutics from $12.00 to $13.00 and gave the stock an “outperform” rating in a report on Friday, October 25th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Aquestive Therapeutics presently has an average rating of “Buy” and a consensus target price of $8.83.

Aquestive Therapeutics Stock Up 6.6 %

AQST opened at $5.07 on Wednesday. The company’s 50-day moving average price is $4.91 and its two-hundred day moving average price is $3.83. Aquestive Therapeutics has a twelve month low of $1.55 and a twelve month high of $6.23. The stock has a market cap of $461.67 million, a price-to-earnings ratio of -11.27 and a beta of 2.82.

Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings data on Monday, November 4th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The company had revenue of $13.54 million during the quarter, compared to analyst estimates of $12.69 million. During the same quarter last year, the firm posted ($0.03) EPS. As a group, sell-side analysts anticipate that Aquestive Therapeutics will post -0.48 earnings per share for the current year.

Institutional Trading of Aquestive Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of AQST. Janney Montgomery Scott LLC bought a new position in Aquestive Therapeutics in the 1st quarter valued at $1,456,000. Vanguard Group Inc. boosted its stake in Aquestive Therapeutics by 71.7% during the first quarter. Vanguard Group Inc. now owns 3,242,571 shares of the company’s stock valued at $13,813,000 after buying an additional 1,353,518 shares during the period. Blue Owl Capital Holdings LP grew its position in Aquestive Therapeutics by 30.3% during the second quarter. Blue Owl Capital Holdings LP now owns 1,140,000 shares of the company’s stock worth $2,964,000 after buying an additional 265,000 shares in the last quarter. Bank of New York Mellon Corp purchased a new position in Aquestive Therapeutics during the second quarter worth about $594,000. Finally, Lazard Asset Management LLC increased its stake in Aquestive Therapeutics by 115.5% in the 1st quarter. Lazard Asset Management LLC now owns 29,112 shares of the company’s stock worth $124,000 after acquiring an additional 15,601 shares during the last quarter. Institutional investors own 32.45% of the company’s stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.